# A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

> **NCT05704738** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 532 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05704738
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-20
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-11-25
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704738, "A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05704738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*